We have shown that the second-generation bis-aryl urea FLT3 inhibitor quizartinib is a potent inhibitor of drug transport by ABCG2 at clinically targeted concentrations and thus may sensitize AML cells expressing ABCG2 to ABCG2 substrate chemotherapy drugs. Here, FLT3 is linked to acute myeloid leukemia.